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The adapter protein MyD88 adapter-like (Mal), encoded by
TIR-domain containing adapter protein (Tirap) (MIM 606252),
is the most polymorphic of the five adapter proteins involved in
Toll-like receptor signaling, harboring eight non-synonymous
single nucleotide polymorphisms in its coding region. We
screened reported mutations of Mal for activity in reporter
assays to test the hypothesis that variants of Mal existed with
altered signaling potential. A TIR domain variant, Mal D96N
(rs8177400), was found to be inactive. In reconstituted cell lines,
Mal D96N acted as a hypomorphic mutation, with impaired
cytokine production and NF-B activation upon lipopolysac-
charide or PAM2CSK4 stimulation. Moreover, co-immunopre-
cipitation studies revealed that Mal D96N is unable to interact
with MyD88, a prerequisite for downstream signaling to occur.
Computer modeling data suggested that residue 96 resides in
the MyD88 binding site, further supporting these findings.
Genotyping of Mal D96N in three different cohorts suggested
that it is a raremutation.We, thus, describe a rare variant inMal
that exerts its effect via its inability to bind MyD88.
TLRs5 are the first line of defense against a diverse range of
pathogens, recognizing pathogen-associated molecular pat-
terns ofmicrobes and initiating an innate immune response (1).
TLR2 recognizes lipopeptide from the cell walls of bacteria,
whereas TLR4 (together withMD-2) is the receptor for LPS (2).
The adapter protein Mal/TIRAP (hereafter referred to as Mal)
is involved in the MyD88-dependent pathway downstream of
TLR2 and TLR4 (3, 4). It acts as a bridging adapter between the
receptor and the sorting adapterMyD88 (5). Upon activation of
TLR2 or TLR4, a signaling cascade is initiated which leads to
the activation of transcription factors such as nuclear factor-B
(NF-B), interferon regulatory factor 5 (IRF5), and activator
protein (AP-1), ultimately culminating in the production of
pro-inflammatory cytokines (6).
The importance of single nucleotide polymorphisms (SNPs)
in TLR-related proteins and their association with various
infectious and inflammatory diseases have recently emerged (7,
8). Notable among them is a study by Khor et al. (9), who
reported that individuals heterozygous for the polymorphism
S180L inMal are protected against pneumococcal disease, bac-
teremia,malaria, and tuberculosis (9).Within the coding region
of a gene, SNPs can alter the characteristics and affect the ability
of a protein to function (10). Interestingly,Mal is themost poly-
morphic of all adapter proteins, harboring at least eight non-
synonymous variants in its coding region. It, thus, appears to be
an important candidate for studying genetic variation in rela-
tion to TLR2 and TLR4 signaling.
In the present study we characterized the known polymor-
phisms in the coding region ofMal for effects on the function of
Mal. We report that one of the mutations in the TIR domain of
Mal, D96N, is broadly defective inTLR2 and theMyD88branch
of the TLR4 signaling pathway. We show by biochemical and
computermodeling data that the basis of this abnormality is the
inability of Mal D96N to bind MyD88. Although the incidence
of this lesion in humans is not known, we screened three small
populations for the defect and found a single heterozygous indi-
vidual, suggesting that D96N is a raremutation.We, thus, iden-
tify a mutation inMal that causes a structural change, affecting
the ability of the protein to bind the downstream effector
MyD88.
EXPERIMENTAL PROCEDURES
Plasmids and Site-directed Mutagenesis—Most of the con-
structs described in this work have been described elsewhere.
These include pEF-BOS-Mal-FLAG (11), pCDNA3-MyD88CFP
(12), pCMV-IRF5-FLAG (13), NF-B-luciferase, interferon-
stimulated response element (ISRE)-luciferase, and Renilla-lu-
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ciferase (14), and the retroviral vector pMSCV2.2-IRES-GFP
(15). pEF-BOS-Mal-FLAG and pMSCV2.2-IRES-GFP-human-
Mal with the different mutations in the Tirap gene were gener-
ated by using a site-directed mutagenesis QuikChange kit
(Stratagene) per the manufacturer’s instructions.
Reconstitution of ImmortalizedMal Knock-out Macrophages—
The immortalized Mal-deficient macrophage-like cell line was
transduced with the retrovirus MSCV2.2. Equal expression of
Mal or the Mal variants in selected clones was confirmed by
Western blotting with anti-FLAG antibody. A Mal antibody (a
gift from S. Akira (16)) was used to compare the expression of
endogenous protein in wild type cells with that of the trans-
duced cell lines.
Luciferase Reporter Assay—HEK293T cells were seeded into
96-well plates at a density of 20,000 cells per well and trans-
fected 16 h later with 40 ng of the indicated luciferase reporter
genes and the indicated amounts of Mal (WT or polymorphic)
usingGeneJuice (EMDBiosciences, SanDiego, CA). In the case
of Fig. 1B, IRF5 construct (10 ng) was co-transfected. The thy-
midine kinase Renilla-luciferase reporterwas co transfected (40
ng) to normalize the data for transfection efficiency. Two days
later reporter gene activity was measured using the Dual Lucif-
erase assay system (Promega).
Enzyme-linked Immunosorbent Assay—Cells were seeded
into 96-well plates at a density of 20,000 cells per well and stim-
ulated overnight with the indicated concentrations of the TLR
ligands. Cell culture supernatants were assayed for TNF with
enzyme-linked immunosorbent assay kits from R&D systems,
according to the manufacturer’s instructions.
Quantitative Real-time PCR—Wild type, Mal-deficient, or
D96N-expressing macrophages were plated at a density of 2 
106 cells per well in a 6-well plate. They were stimulated for 100
ng/ml LPS for 2 h. RNA extraction and IFN-mRNA induction
analysis by quantitative Real-time PCR was carried out as
described elsewhere (17).
IkB Degradation Assay—2  106 cells were seeded per well
into a 6-well plate. After 24 h the cells were treated with 10 nM
PAM2CSK4 or 100 ng/ml LPS for the indicated time intervals.
Cell lysates were made and run on an 8–16% SDS gel (NuSep),
transferred to nitrocellulose membrane, and probed with anti-
IkB. (Cell Signaling Technology).
Immunoprecipitations and Immunoblots—HEK293T cells
were transfected with TLR2-YFP, TLR4-CFP, or MyD88-CFP
and FLAG-taggedMal (WTorD96N). Two days post-transfec-
tion, cells were harvested, and the lysates were incubated over-
night with polyclonal anti-GFP antibody (Invitrogen) and poly-
A-Sepharose beads. Rabbit IgG was used as a control. The
processed samples were run on an SDS gel, transferred to nitro-
cellulose membrane, and probed with a horseradish peroxi-
dase-conjugated anti-FLAGantibody (SIGMA,MO,USA). The
immunoprecipitation of TLR2-YFP, TLR4-CFP and MyD88-
CFPwas checked by immunoblotting the samemembranewith
monoclonal anti-GFP antibody (Invitrogen, CA, USA). Expres-
sion level of the proteins in whole cell lysates was checked by
immunoblotting with horseradish peroxidase-conjugated anti-
FLAG antibody and monoclonal anti-GFP antibody.
Molecular Modeling of Mal D96N—The amino acid
sequences and three-dimensional structures of the TIR
domains of TLR1 andTLR2, homologous proteins used as tem-
plates for comparative modeling, were obtained from the Pro-
tein Data Bank. Initial alignments between Mal and its tem-
plates were obtained using the program FUGUE (18). Models
were produced using the program MODELLER (19) as previ-
ously described (20). Site-directed Mutator (21) was used to
calculate a stability score for a specific point mutation (96N) in
the Mal TIR model. Three-dimensional structure visualization
and image generation was carried out using Pymol (38).
Genotyping of TIRAP D96N in Human Subjects—Genetic
studies were approved by the Ethical Committee of the Rad-
boud University Nijmegen, The Netherlands. Genomic DNA
from 91 African Tanzanians, 97 Chinese Han, and 188 Cauca-
sian Dutch individuals (22) were screened for the presence of
TIRAP D96N (which encodes for Mal D96N). Screening was
performed by PCR amplification and sequencing. For ampli-
fication, the forward primer 5-AGTGAGAGGGCACCTG-
GTAA-3 and the reverse primer 5-CACAGCTCGGACA-
CTATAGCGCC-3 were used. Sequencing was performed
with the same primers on a 3730 DNA Analyzer (Applied
Biosystems, Foster City, CA) by the DNA Sequencing Facil-
ity, Radboud University.
RESULTS
Transient Expression of D96N Does Not Activate NF-B and
ISRE Reporters—The non-synonymous SNPs occurring in the
coding region of humanMal were selected from the NCBI SNP
data base. These were examined for their ability to drive two
signaling pathways known to function downstream of Mal.
Transient expression of WT Mal in HEK293T cells triggers
activation of NF-B- and IRF5-dependent ISRE luciferase
reporters (23, 24). Notably, IRF5 is activated downstream of
Mal andMyD88 but not TRIF or TRAM (24). As expected,WT
Mal could drive both reporters. Moreover, four of the five poly-
morphisms screened were comparable to wild typeMal in their
ability to drive both reporters (Fig. 1, A and B). However, Mal
D96Nwas severely compromised in driving either theNF-Bor
the IRF5-ISRE reporter. IRF5 by itself can weakly activate the
ISRE reporter, but the co-expression of wild typeMal leads to a
much greater activation above this background value (Fig. 1B).
In the case of Mal D96N, this increase in activity over the back-
ground level was not seen. These results suggest thatMal D96N
does not drive signal transduction upon overexpression.
The Expression of WT Mal Functionally Complements Mal-
deficient Macrophages—To study these polymorphisms in
phagocytes with a clean genetic background, we immortalized
bone marrow-derived macrophages from wild type and Mal-
deficient mice using a retrovirus encoding several oncogenes
(15, 25). These cell lines behave similar to their respective pri-
mary bone marrow-derived macrophages (supplemental Fig.
S1). We generated retroviruses expressing FLAG-tagged wild
type Mal in tandem with an internal ribosomal entry site
(IRES)-encoded green fluorescent protein (GFP). This con-
struct expresses a bicistronic mRNA that allows the translation
of both Mal and GFP in the Mal-deficient immortalized cell
line. The transduced cells were sorted for GFP and then cloned
by limiting dilution. InMal-deficient macrophages, TNF pro-
duction in response to LPS was significantly reduced, whereas
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in response to PAM2CSK4, it was completely abrogated. We
examined TNF production in the clone obtained from trans-
ducing Mal-deficient cell line with retrovirus expressing WT
Mal. The single cell clone could completely restore responsive-
ness to LPS and PAM2CSK4 stimulation (Fig. 2A). Similarly,
cells lines expressing each of the variant forms of Mal were
generated. Clones with similar levels of expression of Mal, as
assessed by Western blot, were selected for further study
(Fig. 2B).
Mal D96N Has Impaired Cytokine Production—Reconsti-
tuted cell lines were stimulated with LPS and PAM2CSK4, and
the pro-inflammatory cytokine TNF was measured in cell
supernatants by enzyme-linked immunosorbent assay. The
variants A9P, R13W, S180L, and V197I were fully functional
and produced comparable levels of TNF as WT cells. How-
ever, in agreement with our earlier experiments, D96Nwas sig-
nificantly compromised in its ability to produce pro-inflamma-
tory cytokines upon stimulation (Fig. 2C). The production of
another proinflammatory cytokine, interleukin-6, was similar
to TNF (data not shown). As a control, TNF production by
the double-stranded RNA mimetic poly I:C stimulation was
also measured. Poly(IC) is a TLR3 ligand whose signaling is
independent ofMal (26). In this case, TNF production in cells
expressing the D96Nmutation was comparable withWTmac-
rophages as well as to cells expressing the different variants of
Mal. To test whether the MyD88-independent TLR4 signal-
ing is intact in D96N-expressing cells, we measured induc-
tion of IFN- mRNA upon LPS stimulation using real-time
PCR (Fig. 2D). D96N expressing macrophages induced com-
parable amounts of IFN- mRNA as WT and Mal-deficient
cells. Thus, macrophages expressing the D96N variant of
Mal are defective in signaling through TLR2 and the MyD88
branch of TLR4, whereas signaling initiated through other
TLRs occurs normally.
IB Degradation Assays—NF-B is the predominant tran-
scription factor responsible for pro-inflammatory cytokine
production downstream of TLR2- and MyD88-dependent
TLR4-signaling pathways. We, therefore, examined the activa-
tion of NF-B (via IB degradation) after LPS and PAM2CSK4
treatment in the reconstituted cell
lines mentioned above. InMal-defi-
cientmacrophages, IBdegradation
is abrogated uponPAM2CSK4 treat-
ment, whereas for LPS stimulation
Mal-deficient macrophages undergo
delayed degradation (27). In WT
bone marrow-derived macro-
phages, IB was completely de-
graded at 10 min after LPS or
PAM2CSK4 treatment (Fig. 3, row
A). As expected, Mal-deficient bone
marrow-derivedmacrophages had a
delayed degradation profile in the
case of LPS (Fig. 3, left panel, row B)
and exhibited no degradation in the
case of PAM2CSK4 treatment (Fig.
3, right panel, row B). Immortalized
wild type and Mal-deficient cell
lines mimicked their primary cell types (Fig. 3, rows C and D).
Mal-deficient cell lines expressing wild type Mal, A9P, R13W,
S180L, or V197I degraded IB at 10 min, like the wild type
immortalized cells (Fig. 3, rows E--G, I, and J). In contrast, how-
ever, and in agreement with the cytokine data, cells expressing
the D96N mutant behaved like the Mal-deficient cells (Fig. 3,
row H), with no degradation in the case of PAM2CSK4 and a
delayed degradation profile after LPS treatment. Glyceralde-
hyde-3-phosphate dehydrogenase was used as an internal load-
ing control. Thus, Mal D96N is a hypomorphic, if not a null
variant of Mal, fully defective in NF-B activation.
Interaction Studies with TLR4, TLR2, and MyD88—Having
established the failure ofMal D96N to signal, we next sought an
explanation for the inability of D96N to transduce the signal
downstream of TLR2 and TLR4. It is thought that Mal acts as a
bridging adapter between the receptor (TLR2 or TLR4) and
MyD88 and, thus, physically interacts with both (28). We,
therefore, examined whether the D96N mutation affected the
ability of Mal to interact with TLR2, TLR4, or MyD88. Tran-
sient transfections in HEK293T cells followed by immunopre-
cipitation assays were carried out to address this question (Fig.
4). As expected, wild type Mal interacted with the receptors
TLR2 (Fig. 4A) and TLR4 (Fig. 4B) and with MyD88 (Fig. 4C,
lane 6). Like wild typeMal, D96N could be co-immunoprecipi-
tated with both TLR2 and TLR4, indicating that this mutation
does not affect the ability of Mal to interact with either of these
receptors. However, D96N was severely compromised in its
ability to interact with MyD88. Although wild type Mal could
co-immunoprecipitate with MyD88, D96N could not (Fig. 4C,
lane 7). Thus, the hypomorphic phenotype of D96N appeared
to result from its inability to interact with MyD88.
Modeling Studies for Mal Suggest That a Change in Surface
Charge Accounts for the D96N Phenotype—We generated high
quality models of the TIR domains of both WT and D96NMal
using the resolved crystal structures of TLR1 and -2 as tem-
plates (29). The Mal TIR domain was predicted to have good
geometry, with none of its - dihedral angles within the dis-
allowed regions of a Ramachandran plot and 90.6% in geomet-
rically favored regions. JOY and Verify3D outputs (20) revealed
FIGURE 1. Human Mal carrying the D96N mutation is unable to activate either NF-B or IRF5. HEK293T
cells were transfected with different variants of Mal and either NF-B luciferase (A) or IRF5 and ISRE-luciferase
reporters (B). 48 h post-transfection, lysates were analyzed for luciferase activity. Renilla-luciferase activity was
used to normalize for transfection efficiency. Results are reported as the mean of triplicate determinations
S.D. Each graph is representative of three (A) or two (B) independent experiments. RLU, relative luciferase
units.
Mal Variant Affects MyD88 Binding















that the environment of residues in themodel ofMal are similar
to those of the TLR1 and TLR2 TIR domains used as templates
and were not energetically unfavorable. Residue Asp-96 was
predicted to lie on the surface of the TIR domain in a highly
negatively charged region. Mal D96N was modeled using the
same approach as the wild type protein and exhibited no signif-
icant changes in structure or geometry compared with wild
type Mal, as might have been expected from a change in a sur-
face residue. This prediction was further supported using soft-
ware capable of estimating the level of structural destabilization
encoded by point mutations (site-directed mutator or SDM)
(21). This program uses a statistical potential energy function
that predicts the effect that a spe-
cific amino acid substitution may
have on the stability of that protein
and produces the pseudo-free
energy difference between a wild
type and mutant protein (21, 30).
The D96N substitution was shown
to induce structural alterations with
corresponding pseudo G values
of 0.729 kcal/mol, implying that
there is no significant change to the
overall stability of the Mal TIR
domain caused by this mutation.
The loss of a surface-exposed
negatively charged side chain
resulting from an aspartic acid to
asparagine substitution (Asp 3
Asn) (Fig. 5A) would be predicted to
be responsible for the experimen-
tally observed disruption of the
Mal/MyD88 protein interaction.
Fig. 5B shows a model of the TLR4-
TIR homodimer (cyan)-Mal TIR
domain (magenta) complex. The
change in electrostatic charge
resides near a surface region (pat-
tern 108–122; shown in yellow) that
is predicted to interact with MyD88
(Fig. 5B and Ref. 20). Moreover, res-
idue 96 lies distal to the BB loop
region of Mal (green) that has previ-
ously been proposed to interact
with TLR4 (Fig. 5B and Ref. 20),
consistentwith the immunoprecipi-
tation studies in Fig. 4 indicating
that Mal D96N retains its ability to
bind to TLRs 2 and 4 even though it
is no longer capable of binding
MyD88.
Genotyping of TIRAP in Human
Populations—Mal D96N is an in-
activatingmutation that is unable to
transduce signaling downstream of
TLR2 andTLR4.Wenext addressed
the question of what the frequency
of this polymorphism was in the
general population.We sequenced Tirap in African Tanzanian
(n 91), ChineseHan (n 97), andCaucasianDutch (n 188)
individuals. The African Tanzanian and the Chinese individu-
als all apparently expressed wild type Mal. However, one indi-
vidual in the Caucasian Dutch cohort was heterozygous for the
D96Nmutation. Although this experiment is not an exhaustive
assessment of the frequency of MalD96N in all populations, we
can conclude that this variation of Mal has a very low preva-
lence in the populations studied. This is understandable given
the strong phenotype in innate signaling that we observed
in our experiments. Indeed, individuals homozygous for
MalD96N would be expected to have a phenotype similar to
B
FIGURE 2. D96N has impaired cytokine production in response to TLR2 or TLR4 ligands. A, functional
restoration of Mal-deficient immortalized macrophage cell line. Immortalized Mal knock-out (ko) cells were
transduced with a retrovirus carrying FLAG-tagged Mal. Single cell clones were selected and tested for their
responsiveness to LPS and PAM2CSK4. B, the same strategy was used to generate cell lines expressing the
different variants of Mal. For each cell line clones were chosen for further study based on similar levels of
expression of Mal or the Mal variant. IB, immunoblot. C, immortalized Mal-deficient macrophage cell lines
expressing either WT Mal or one of the variants were stimulated with LPS, PAM2CSK4, and poly I:C overnight.
The supernatants were then analyzed for TNF levels. Poly I:C, a TLR3/TRIF ligand, was used as a control for
Mal-independent signaling. Results are reported as the mean of triplicate determinations S.D. Each graph is
representative of three independent experiments. D, immortalized WT and Mal-deficient (Mal ko)- and Mal-
deficient macrophages (Mal ko  D96N)-expressing D96N were stimulated for 2 h with LPS (100 ng/ml). Total
RNA was extracted. Levels of mRNA for IFN- were determined by quantitative real-time-PCR and normalized
to hypoxanthine phosphoribosyltransferase 1 (HPRT1) level of expression. Results are reported as the mean of
duplicate determinations S.D. This graph is representative of one of two independent experiments. Bl, blank.
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what has been reported forMyD88 deficiency, i.e. hypersuscep-
tible to common life-threatening pathogens such as Streptococ-
cus pneumoniae (31).
DISCUSSION
TLRs are the key sensors of microbial infection in mammals.
Upon encountering a pathogen, they elicit an inflammatory
response involving an intricate network of signaling molecules.
Changes in the structure of the TLR signaling components can
have dramatic effects on the outcome of various infectious dis-
eases. Some of these changes may be caused by the presence of
a SNP in the coding region of the protein. The effects of SNPs
on the structure of proteins and the consequent effect on TLR
signaling have been described in many studies (32–35).
TIR domain interactions between the TLR components are a
necessary event for downstream signaling to occur. SNPs in
adapter proteins could, thus, be influential in determining the
progression of infection. Incidentally,Mal is themost polymor-
phic of all the adapter proteins. Of the eight known coding
polymorphisms in Mal, only one, S180L, has been previously
described (9). Khor et al. (9) found that the heterozygotes car-
rying this polymorphism were protected from malaria, tuber-
culosis, and bacteremia. In view of these observations we
hypothesized that SNPs in Mal could affect TLR2 and TLR4
signaling.
The data presented herein make a strong case that a variant
of Mal, D96N, is essentially nonfunctional. Our model would
indicate that Mal D96N does not bind MyD88 because of a
critically located change in charge on its surface and, hence,
fails to function as a bridging adapter between the receptors
TLR2 and TLR4 and the sorting adapterMyD88. Its inability to
engage MyD88 prevents activation of NF-B, IRF5, and most
likely activator protein (AP-1), all of which are required to trig-
ger pro-inflammatory cytokine production.
A noteworthy point is that Mal-deficient macrophages from
mice were all reconstituted with humanMal. The TIR domains
of murine and human Mal are 71%
identical, and indeed, human Mal
was capable of fully restoring func-
tion in these cells. As expected,
D96N was defective in pro-inflam-
matory cytokine production upon
stimulation. A surprising finding
was the absence of a phenotype for
Mal S180L in our studies, an out-
come that conceivably could be
because of differences in species of
the reconstituted protein and cell
types, although this explanation
would not hold for the ability of
transfected Mal S180L to drive
reporter constructs in HEK293T
cells. In our experimentsMal S180L
was fully active, and its effect upon
stimulation was comparable with
that of wild type Mal. It is true that
we have no truly satisfactory expla-
nation for the discrepancy between
our findings and that of Khor et al. (9). One explanation for our
findings, at least in Mal knock-out macrophages comple-
mented with the various mutant Mal constructs, is that Mal
S180L may be a hypomorphic lesion rather than a null muta-
tion. Hence, sufficient overexpression may overcome its rela-
tive inability to signal. Indeed, Western blots of the transduced
Mal as well as the variants using an established anti-Mal anti-
body suggested that the recombinant proteins were at least
10–100-foldmore abundant in the immortalized cell lines than
endogenous wild type Mal (data not shown). Clearly, this dis-
crepancy from previously published results needs to be better
analyzed. To this effect, a knock-inmouse expressing the S180L
lesion has been engineered (data not shown) andwill need to be
characterized to determine the nature of this mutation in vivo.
Residue 96 and the surrounding 10–12 amino acid region is
fairly well conserved in the known orthologs of TIRAP. The
presence of an aspartic acid (Asp) at position 96 creates a neg-
atively charged surface that is conducive to protein-protein
interactions. Conversion to uncharged asparagine would, thus,
be expected to change the binding potential of the protein.
Modeling of the TIR domains of Mal and Mal D96N suggested
that the residue 96 lies away from the TLR4 or TLR2 binding
site but is in very close proximity to the MyD88 binding site
(Fig. 5). These predictions were confirmed in co-immunopre-
cipitation assays and show that Mal D96N retains the ability to
bind TLR2 and TL4 but is unable to bind MyD88. Hence, this
characterization of a natural Mal mutant identifies with appar-
ent pinpoint precision a single residue in theTIRdomain ofMal
that is critical for its interaction with MyD88.
The frequency of D96N in the populations we analyzed was
very low. In the initial screen we genotyped individuals from
three different populations. However, we found just one indi-
vidual (of 376) who was heterozygous for D96N. Considering
the deleterious phenotypewe observe, the low frequency of this
polymorphism is not unexpected. As the mutation exists, it is
nearly certain that there are sporadic individuals born who are
FIGURE 3. Mal D96N fails to degrade IB- effectively. NF-B activation in the reconstituted cell lines was
examined via IB- degradation assay. The cells were stimulated with LPS (left panel) or PAM2CSK4 (right panel)
for the indicated time points, and the whole cell lysates loaded on a denaturing gel, transferred to nitrocellu-
lose membrane, and blotted with IB- antibody. Levels of glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) act as an internal loading control. WT, wild type; ko, knock out; WB, Western blot.
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homozygous for D96N. Because the data suggest the failure to
bind MyD88 is the reason for the phenotype of D96N, we
believe that individuals carrying thismutation in a homozygous
state would be extremely susceptible to both Gram-negative
and Gram-positive infections. In view of the reported serious
clinical significance of MyD88 and IRAK4 deficiencies, two
gene products that are downstreamofMal andwhich should be
similar to Mal D96N expression, we believe that Mal D96N
represents a rare, potentially life-threateningmutation (36, 37).
Indeed, individuals occasionally present for medical case with
sepsis in the absence of any known risk factors; we would sug-
gest that MalD96N should be considered under such circum-
stances as a potential cause of such a clinical presentation.
In contrast to what one might expect for the rare individual
with two mutant alleles, the fact that this amino acid variant
exists in the population, albeit at a very low frequency, suggests
that heterozygous individuals have a survival advantage under
some, but still undefined, circumstances. The key to determin-
ing the nature of this hypothetical heterozygous advantage is to
analyze enough individuals from enough different populations
to define clinical correlates.
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FIGURE 4. D96N fails to interact with MyD88. HEK293T cells were plated to
half confluence in six-well plates. After attachment, cells were transiently
transfected with either TLR2-YFP (A), TLR4-CFP (B), or MyD88-CFP (C) and
FLAG-tagged Mal WT or Mal D96N. Two days after transfection, supernatants
were removed, and cells were lysed. Anti-GFP polyclonal antibody was used
for immunoprecipitation (IP). Immunoprecipitates were loaded on a denatur-
ing gel, transferred to nitrocellulose membrane, and visualized with a mono-
clonal anti-FLAG-horseradish peroxidase antibody. The immunoprecipitation
of TLR2-YFP, TLR4-CFP, and MyD88-CFP was confirmed by immunoblotting
the membrane with anti-GFP antibody. The same antibodies were used to
check the level of expression of the proteins in whole cell lysates. IB,
immunoblot.
FIGURE 5. The D96N mutation results in a loss of negative charge on the
surface of the Mal-TIR domain in a region predicted to be involved in
MyD88, but not TLR interactions. A, comparison of the electrostatic sur-
faces of wild-type (left) and Asn-96 (right) Mal-TIR models, indicating a loss of
negative charge (red) in the region of residue 96 (circled). B, model of the
TLR4-TIR homodimer (cyan)/Mal TIR domain (magenta) complex (20), indicat-
ing the location of Mal-D96 (red, space fill), its proximity to the predicted
MyD88 interaction surface (pattern 108 –122, yellow), and its distance from
the BB-loop region (green) that is vital for the interaction of Mal with TLR4
(cyan).
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